Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.
Ontology highlight
ABSTRACT: Targeted gene therapy is a promising approach for treating prostate cancer after the discovery of prostate cancer-specific promoters such as prostate-specific antigen, rat probasin, and human glandular kallikrein. However, these promoters are androgen dependent, and after castration or androgen ablation therapy, they become much less active or sometimes inactive. Importantly, the disease will inevitably progress from androgen-dependent (ADPC) to castration-resistant prostate cancer (CRPC), at which treatments fail and high mortality ensues. Therefore, it is critical to develop a targeted gene therapy strategy that is effective in both ADPC and CRPC to eradicate recurrent prostate tumors. The human telomerase reverse transcriptase-VP16-Gal4-WPRE integrated systemic amplifier composite (T-VI
SUBMITTER: Xie X
PROVIDER: S-EPMC4120838 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA